JP6519038B2 - 脳梗塞治療のための多能性幹細胞 - Google Patents

脳梗塞治療のための多能性幹細胞 Download PDF

Info

Publication number
JP6519038B2
JP6519038B2 JP2014035725A JP2014035725A JP6519038B2 JP 6519038 B2 JP6519038 B2 JP 6519038B2 JP 2014035725 A JP2014035725 A JP 2014035725A JP 2014035725 A JP2014035725 A JP 2014035725A JP 6519038 B2 JP6519038 B2 JP 6519038B2
Authority
JP
Japan
Prior art keywords
cells
negative
cell
pluripotent stem
cell preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2014035725A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015159895A (ja
JP2015159895A5 (enExample
Inventor
正順 吉田
正順 吉田
真理 出澤
真理 出澤
悌二 冨永
悌二 冨永
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tohoku University
Life Science Institute Ltd
Original Assignee
Tohoku University
Life Science Institute Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tohoku University, Life Science Institute Ltd filed Critical Tohoku University
Priority to JP2014035725A priority Critical patent/JP6519038B2/ja
Priority to US14/695,843 priority patent/US20160082048A1/en
Publication of JP2015159895A publication Critical patent/JP2015159895A/ja
Priority to US15/413,086 priority patent/US10993966B2/en
Publication of JP2015159895A5 publication Critical patent/JP2015159895A5/ja
Application granted granted Critical
Publication of JP6519038B2 publication Critical patent/JP6519038B2/ja
Priority to US17/219,430 priority patent/US20210213068A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
    • A61K35/545—Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Reproductive Health (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Materials For Medical Uses (AREA)
JP2014035725A 2014-02-25 2014-02-26 脳梗塞治療のための多能性幹細胞 Active JP6519038B2 (ja)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP2014035725A JP6519038B2 (ja) 2014-02-26 2014-02-26 脳梗塞治療のための多能性幹細胞
US14/695,843 US20160082048A1 (en) 2014-02-26 2015-04-24 Pluripotent stem cell for treatment of cerebral infarction
US15/413,086 US10993966B2 (en) 2014-02-26 2017-01-23 Pluripotent stem cell for treatment of cerebral infarction
US17/219,430 US20210213068A1 (en) 2014-02-25 2021-03-31 Pluripotent stem cell for treatment of cerebral infarction

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2014035725A JP6519038B2 (ja) 2014-02-26 2014-02-26 脳梗塞治療のための多能性幹細胞

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018074932A Division JP6604492B2 (ja) 2018-04-09 2018-04-09 脳梗塞治療のための多能性幹細胞

Publications (3)

Publication Number Publication Date
JP2015159895A JP2015159895A (ja) 2015-09-07
JP2015159895A5 JP2015159895A5 (enExample) 2017-02-09
JP6519038B2 true JP6519038B2 (ja) 2019-05-29

Family

ID=54183439

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014035725A Active JP6519038B2 (ja) 2014-02-25 2014-02-26 脳梗塞治療のための多能性幹細胞

Country Status (2)

Country Link
US (3) US20160082048A1 (enExample)
JP (1) JP6519038B2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025192800A1 (ko) * 2024-03-15 2025-09-18 가톨릭대학교 산학협력단 Ssea3 및 cd105를 발현하는 신경능 유래 코 줄기세포를 유효성분으로 포함하는 알츠하이머병 예방 또는 치료용 약학적 조성물

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6391364B2 (ja) * 2014-08-25 2018-09-19 国立大学法人 鹿児島大学 認知機能障害改善用細胞製剤
JP6940101B2 (ja) * 2016-01-15 2021-09-22 国立大学法人富山大学 虚血性脳梗塞への多能性幹細胞の動員
SG11201810188VA (en) * 2016-05-16 2019-02-27 Univ Nagoya Nat Univ Corp Amelioration and treatment of perinatal brain damage with pluripotent stem cells
WO2018021515A1 (ja) * 2016-07-29 2018-02-01 国立大学法人東北大学 血管障害の予防又は治療剤
CA3032925A1 (en) * 2016-08-03 2018-02-08 Life Science Institute, Inc. Alleviation and treatment of ischemia reperfusion-induced lung injury using pluripotent stem cells
SG11201900983TA (en) * 2016-08-03 2019-03-28 Univ Nagoya Nat Univ Corp Amelioration and treatment of chronic lung disease using pluripotent stem cells
EP3508207B1 (en) 2016-08-30 2021-08-11 Niigata University Cell preparations cultivated under low oxygen and sugar conditions, and their uses in therapy.
CN110869034A (zh) * 2017-06-20 2020-03-06 国立大学法人名古屋大学 利用多能干细胞进行的伴随胎儿生长迟缓的脑损伤的改善和治疗
JP6604492B2 (ja) * 2018-04-09 2019-11-13 株式会社生命科学インスティテュート 脳梗塞治療のための多能性幹細胞
CN110772535A (zh) * 2018-07-12 2020-02-11 南通大学 多系分化持续应激细胞在制备镇痛药物中的应用
CA3150769A1 (en) * 2019-08-09 2021-02-18 Tohoku University Agent for treating or preventing vascular dementia
CN110693908A (zh) * 2019-10-15 2020-01-17 南通大学 多系分化持续应激细胞的应用、治疗周围神经损伤药物及其制备方法
JP7658917B2 (ja) * 2020-01-08 2025-04-08 公益財団法人神戸医療産業都市推進機構 身体機能回復促進剤
US20230203436A1 (en) 2020-04-02 2023-06-29 Tohoku University High-potential pluripotent stem cells
JP2025123077A (ja) * 2024-02-09 2025-08-22 国立大学法人東北大学 脊髄梗塞治療のための多能性幹細胞

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060210544A1 (en) * 2003-06-27 2006-09-21 Renomedix Institute, Inc. Internally administered therapeutic agents for cranial nerve diseases comprising mesenchymal cells as an active ingredient
US9550975B2 (en) * 2009-07-15 2017-01-24 Mari Dezawa SSEA-3 pluripotent stem cell isolated from body tissue

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025192800A1 (ko) * 2024-03-15 2025-09-18 가톨릭대학교 산학협력단 Ssea3 및 cd105를 발현하는 신경능 유래 코 줄기세포를 유효성분으로 포함하는 알츠하이머병 예방 또는 치료용 약학적 조성물

Also Published As

Publication number Publication date
JP2015159895A (ja) 2015-09-07
US20170128494A1 (en) 2017-05-11
US20210213068A1 (en) 2021-07-15
US20160082048A1 (en) 2016-03-24
US10993966B2 (en) 2021-05-04

Similar Documents

Publication Publication Date Title
US20210213068A1 (en) Pluripotent stem cell for treatment of cerebral infarction
Pal et al. Ex vivo-expanded autologous bone marrow-derived mesenchymal stromal cells in human spinal cord injury/paraplegia: a pilot clinical study
JP2013508013A (ja) 細胞療法戦略を用いた慢性神経組織損傷の治療方法
WO2014027684A1 (ja) 心筋梗塞の修復再生を誘導する多能性幹細胞
JP6401757B2 (ja) 臍帯血細胞を用いた脳損傷の処置
Okur et al. The effect of umbilical cord-derived mesenchymal stem cell transplantation in a patient with cerebral palsy: a case report
JP7255805B2 (ja) 多能性幹細胞による胎児発育不全に伴う脳障害の改善及び治療
JP2015160820A (ja) 慢性腎障害治療のための多能性幹細胞
JP6604492B2 (ja) 脳梗塞治療のための多能性幹細胞
JP7029729B2 (ja) 血管障害の予防又は治療剤
JP7072777B2 (ja) 慢性腎障害治療のための多能性幹細胞
JP6994200B2 (ja) 多能性幹細胞による周産期脳障害の改善及び治療
JP7618233B2 (ja) 脳血管性認知症の治療または予防剤
JP7076709B2 (ja) 間葉系幹細胞活性化剤
US20210228638A1 (en) Therapeutic agent for spinal cord injury
WO2025170054A1 (ja) 脊髄梗塞治療のための多能性幹細胞
Bertuzzi et al. Stem cell’s behavioral effects in rats in a model of Alzheimer’s disease
US20250295703A1 (en) Treatment agent for hair damage
JP2023041486A (ja) 毛髪損傷の治療剤
WO2021085639A1 (ja) 多能性幹細胞による間質性膀胱炎の治療
Ourique et al. Advances in Stem Cells

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161221

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20161221

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20171003

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A712

Effective date: 20171201

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171204

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20180109

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180409

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20180704

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20180727

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20190402

R150 Certificate of patent or registration of utility model

Ref document number: 6519038

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313117

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250